High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine
暂无分享,去创建一个
H. Koga | Toru Nakamura | T. Torimura | J. Akiba | T. Kakuma | H. Yano | H. Iwamoto | Mitsuhiko Abe | T. Niizeki | Toshimitsu Tanaka | Atsutaka Masuda | Takahiko Sakaue | Yu Ikezono | Fumitaka Wada
[1] Lijiang Hu,et al. Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy , 2019, Oxidative medicine and cellular longevity.
[2] M. Kudo. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update , 2017, Oncology.
[3] J. Blanc,et al. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma , 2017, Expert opinion on emerging drugs.
[4] H. El‐Serag,et al. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. , 2017, Gastroenterology.
[5] Y. Einaga,et al. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205) , 2017, Gastric Cancer.
[6] H. Saya,et al. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus‐positive patients with resected hepatocellular carcinoma , 2016, Cancer science.
[7] H. Koga,et al. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study , 2016, Cancer Chemotherapy and Pharmacology.
[8] H. Koga,et al. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study , 2015, Cancer medicine.
[9] Xiaowu Li,et al. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients , 2014, Diagnostic Pathology.
[10] S. Okazaki,et al. Redox regulation in stem-like cancer cells by CD44 variant isoforms , 2013, Oncogene.
[11] T. Hibi,et al. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence , 2013, British Journal of Cancer.
[12] R. Poon,et al. Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. , 2012, Current cancer drug targets.
[13] H. Saya,et al. CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. , 2012, Cancer research.
[14] Yaoh-Shiang Lin,et al. Nonadhesive Culture System as a Model of Rapid Sphere Formation with Cancer Stem Cell Properties , 2012, PloS one.
[15] V. Rogiers,et al. Successful isolation of liver progenitor cells by aldehyde dehydrogenase activity in naïve mice , 2012, Hepatology.
[16] M. Ohmura,et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. , 2011, Cancer cell.
[17] Xin-guo Jiang,et al. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[18] I. Ng,et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. , 2010, Cell stem cell.
[19] K. Mimori,et al. CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.
[20] T. Masuko,et al. CD44+ slow‐cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis , 2010, Cancer science.
[21] Peng Huang,et al. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.
[22] X. Wang,et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.
[23] S. Fan,et al. Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.
[24] P. Desreumaux,et al. Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence , 2006, Alimentary pharmacology & therapeutics.
[25] Takafumi Yoshida,et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. , 2006, Cancer research.
[26] H. Saya,et al. Mechanism and biological significance of CD44 cleavage , 2004, Cancer science.
[27] S. Pignata,et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial , 2001, Gut.
[28] J. Dick,et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.
[29] M. Kojiro,et al. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells , 1993, Hepatology.
[30] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.